LSL LSL Pharma Group Inc.
LSL Pharma Group Inc. develops, manufactures, and commercializes sterile pharmaceutical products, cosmetic products, and natural health products in Canada, the United States, and internationally. It offers dietary supplements and vitamins in the tablet and capsule form; niche sterile ophthalmic products in the form of ointments and drops; and cosmetic, pharmaceutical, as well as natural health products in sachets, capsules, loose powder, blister packs, and liquids for pharmacy banners and hospitals. The company is headquartered in Boucherville, Canada.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About LSL Pharma Group (CVE: LSL)
›
LSL Pharma Group (CVE: LSL) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 252 employees.
The shares were at 0.3250 CAD on 19 November 2026, down 5.8% over 52 weeks. Its 52-week range is 0.2600 CAD to 0.5600 CAD: the price is 42.0% below the high and 25.0% above the low.
Its market capitalisation is 41.19M CAD.
LSL Pharma Group reports return on equity of -10.5%, an operating margin of -10.2% and revenue up 102.7% year over year.
Its debt exceeds its cash by 49.63M CAD, a debt-to-equity ratio of 1.42. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. One analyst covers the stock, with an average rating of Strong Buy; their mean price target of 0.6000 CAD is 84.6% above the current price.